2023 Highlights, Including Expanded FDA Approval And New Study Publications
In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements. We took a fresh look at our mission statement during the year and refined it to better capture the spirit of what we do each day at Cumberland Pharmaceuticals. It now […]
Third Quarter 2023 Updates, Including Our New Mission Statement
During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows: working together to provide unique products that improve the quality of patient care We took several factors into account in designing this statement. First, […]
Second Quarter 2023 Updates, Including Expanded FDA Approval for Caldolor® and Publication of Newborn Clinical Study Results
In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. We’re pleased to share several notable developments from an overall successful quarter: […]
First Quarter 2023 Updates, Including NOPAIN Act and FDA Fee Waiver
We have continued to successfully manage our business despite the challenges in our operating environment. Our team has remained dedicated to delivering high-quality medicines for our patients, while also developing new medicines for the future. We’re pleased to share several notable developments from the first quarter of 2023: The FDA granted our request for a […]